Nasdaq:CLDX

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease

March 01, 2026 09:45 ET | Source: Celldex Therapeutics, Inc. - Late breaking Poster Presentation at AAAAI -- Ability to…

3 hours ago